SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical trades higher on the bourses

11 Mar 2013 Evaluate

Sun Pharmaceutical is currently trading at Rs. 836.95, up by 18.70 points or 2.29% from its previous closing of Rs. 818.25 on the BSE.

The scrip opened at Rs. 820.00 and has touched a high and low of Rs. 838.50 and Rs. 816.75 respectively. So far 43,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 825.80 on 25-Feb-2013 and a 52 week low of Rs. 535.55 on 16-Mar-2012.

Last one week high and low of the scrip stood at Rs. 822.65 and Rs. 793.85 respectively. The current market cap of the company is Rs. 86,670 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 25.90% and 10.42% respectively.

Sun Pharmaceutical Industries and Taro Pharmaceutical Industries have mutually agreed to terminate their merger agreement, announced in August 2012, pursuant to which all shareholders of Taro other than Sun Pharma and its affiliates would have received a cash payment of $39.50 per share upon the closing of the merger.

Each of Sun Pharma and Taro (at the direction of the Special Committee) agreed that terminating the merger agreement was in the best interest of the respective companies and shareholders.

Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×